Navigation Links
Heparin Based Nanoscale Materials Developed For Dialysis Treatment

In what can be called as a breakthrough in the field of nanotechnology, researchers have been successful in engineering nanoscale biomaterials, using heparin//, an anticoagulant. These blood compatible could revolutionize medical treatments, including dialysis, a routine form of treatment for renal failure patients.

Furthermore, these medical devices could have numerous diagnostic and therapeutic applications that are not foreseen at the moment.

The researchers prepared several materials with heparin composites or coatings, including carbon nanotubes, nanofibers, and membranes with nanosized pores, and then demonstrated the materials' high compatibility with blood. Heparin is a common therapeutic used to maintain blood flow or prevent clotting during medical procedures and treatments.

The researchers demonstrated the composite heparin membrane with nanopores could work as an artificial kidney, or dialyzer, by filtering the blood and maintaining its flow. The presence of this blood-compatible dialyzer could potentially eliminate the need for systemic administration of heparin to the patient during kidney dialysis, the researchers say.

The heparin-coated membranes are described in a paper titled ‘Ionic Liquid-Derived Blood Compatible Membranes for Kidney Dialysis,’ published online Apr. 24 in advance of print in the Journal of Biomedical Materials Research.

‘These heparin composite membranes and fibers and coated carbon nanotubes are an enabling technology,’ says Saravanababu Murugesan, a recent doctoral graduate in chemical and biological engineering at Rensselaer and lead author of the paper. ‘Our results show these novel materials have great promise in the development of improved medical devices that are blood compatible.’

The research team is led by Robert Linhardt, the Ann and John H. Broadbent Jr. '59 Senior Constellation Professor of Bio catalysis and Metabolic Engineering at Rensselaer, and includes collaboration with Pulickel Ajayan, the Henry Burlage Professor of Materials Science and Engineering, and Omkaram ‘Om’ Nalamasu, professor of materials science and engineering, at Rensselaer. Additional co-authors of the paper are Shaker Mousa, director of the Pharmaceutical Research Institute at Albany College of Pharmacy, and Aravind Vijayaraghavan, a recent doctoral graduate in materials science and engineering at Rensselaer. Funding for this research was provided by the National Institutes of Health.

Recent results related to this work have been published online in the journals Langmuir (‘Blood Compatible Nanotubes ??? Nano-based Neoproteoglycans,’ Mar. 11, 2006) and Biomacromolecules (‘Preparation of Biopolymer Fibers by Electrospinning from Room Temperature Ionic Liquids,’ Jan. 26, 2006). Provisional patents have been filed by Rensselaer Polytechnic Institute.

Research in Linhardt's group at the Center for Biotechnology and Interdisciplinary Studies at Rensselaer focuses on complex carbohydrates such as heparin. After determining the structure of these molecules, researchers study their biological activities to establish a structure-activity relationship that may reveal lead compounds for new drug development. Recent discoveries include a synthetic method for preparation of heparin in quantities large enough for use in medical treatment.

Source: Euekalert

Related medicine news :

1. Complications In Kidney Failure Patients Linked To Heparin
2. Heparin does not protect from recurrent heart attacks
3. Heparin Antibodies May Put Patients At Risk
4. Ordinary Heparin as Effective as Expensive Blood Thinner
5. Steps To Improve Quality Of Plant-Based Drugs
6. Cancer hazard Found With Animal-Based Nutrients
7. Prime Minister Manmohan Against Incentive-Based Population Control
8. New Oat And Soy-Based Fat Replacer Launched
9. Record Growth Of Soya-Based Dairy Alternatives Over The Past Year In European Markets
10. Race Based Genome Project Launched By Mexico
11. Childhood Asthma Can Be Kept Under Control By Cost-Effective Home Based Interventions
Post Your Comments:

(Date:12/1/2015)... ... December 01, 2015 , ... McLean, VA., December ... a fixed price per sprint agile development contract to support the National Geospatial-Intelligence ... five years, provides software engineering, infrastructure, as well as operations and sustainment support ...
(Date:12/1/2015)... ... December 01, 2015 , ... TCS ... care management and population health arenas, is pleased to announce that VIP Care ... services, has successfully implemented the ACUITY Complete Care™ Management to back their collaborative ...
(Date:12/1/2015)... CA (PRWEB) , ... December 01, 2015 , ... ... has selected 10 semi-finalists to head to Las Vegas for CES 2016, the world’s ... including CEO of Consumer Technology Association Gary Shapiro, Founding Partner of Pacific Investments Veronica ...
(Date:12/1/2015)... Aliso Viejo, CA (PRWEB) , ... December 01, 2015 , ... ... any length of footage, and with full control over customization, the possibilities are truly ... color, frame rate, position randomization, overlay depth position, vertical flip, horizontal flip, depth of ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... Magazine as a Modern Man for 2015. , Angeleno Magazine is a ... United States. Established in 1994, Modern Luxury includes more than 50 magazine titles ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... 1, 2015 Breg, Inc ., a ... today that it has been awarded three contracts by ... by Novation will have access to improved pricing for ... and soft goods dedicated to advancing orthopedic care.  ... aging U.S. population, rising prevalence of chronic conditions and ...
(Date:12/1/2015)... N.J. , Dec. 1, 2015 ... against HIV/AIDS, Johnson & Johnson (NYSE: JNJ ... its Janssen Pharmaceutical Companies to significantly reduce the ... who make up 74 percent of new HIV ... Announced on World AIDS Day, these new initiatives ...
(Date:12/1/2015)... 1, 2015 Relmada Therapeutics, Inc. (OTCQB: RLMD), a ... pain, announced today that the company will present at the ... 1-3 at the Luxe Sunset Boulevard Hotel in ... of Relmada Therapeutics, will present on Thursday, December 3, at ... . Please register at least 10 minutes prior to ...
Breaking Medicine Technology: